Epigenetic regulators of gamma-globin gene expression (HbF epigenetic regulators)

Epigenetic regulators of gamma-globin gene expression are a diverse group of proteins and enzymes that orchestrate the developmental silencing of fetal hemoglobin (HbF, alpha2gamma2) and the transition to adult hemoglobin (HbA, alpha2beta2) shortly after birth [1.3.1, 1.4.2]. This regulatory network primarily involves key transcriptional repressors such as B-cell lymphoma/leukemia 11A (BCL11A) and Zinc finger and BTB domain-containing 7A (ZBTB7A/LRF), which bind to the gamma-globin (HBG1/HBG2) promoters [1.3.1, 1.3.5]. These repressors recruit multi-protein co-repressor complexes, including the Nucleosome Remodeling and Deacetylase (NuRD) complex, the CoREST complex, and the Direct Repeat Erythroid Definitive (DRED) complex [1.1.1, 1.3.5]. These complexes utilize enzymatic subunits such as histone deacetylases (HDAC1 and HDAC2), lysine-specific demethylase 1 (LSD1/KDM1A), and DNA methyltransferase 1 (DNMT1) to modify the local chromatin environment through deacetylation, demethylation of activating marks (like H3K4me), and DNA methylation, effectively silencing the genes [1.1.4, 1.2.2, 1.3.1]. In patients with beta-hemoglobinopathies like sickle cell disease and beta-thalassemia, pharmacological inhibition of these epigenetic regulators can reactivate gamma-globin expression, leading to the production of HbF which compensates for the lack of functional beta-globin [1.4.1, 1.4.2]. Therapeutic agents targeting this system include DNMT inhibitors like decitabine, HDAC inhibitors such as vorinostat and entinostat, and LSD1 inhibitors like tranylcypromine [1.1.1, 1.3.2, 1.4.4]. While these "HbF inducers" show significant clinical promise, their use is often limited by systemic toxicities, particularly myelosuppression, and the potential for broad, non-specific epigenetic alterations across the genome [1.2.2, 1.3.2].

Other names

Fetal hemoglobin epigenetic regulatorsgamma-globin repressorsHbF regulatorsgamma-globin gene expression regulators

Inhibition of transcriptional repressors (e.g., BCL11A, ZBTB7A) or their associated co-repressor complexes (e.g., NuRD, CoREST, DRED) to prevent DNA methylation and histone deacetylation/demethylation at the gamma-globin (HBG1/HBG2) promoters, thereby maintaining an open chromatin state and inducing fetal hemoglobin (HbF) production.